SCHEMBL1315531

SCHEMBL1315531

COC1(CN)CCN(C(=O)O)CC1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.35
CYP2C19 P33261 5/20 0.33
CYP3A4 P08684 4/20 0.33
MEN1 O00255 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP2C9 P11712 4/20 0.33
ALDH1A1 P00352 3/20 0.33
CYP1A2 P05177 3/20 0.33
USP2 O75604 2/20 0.33
HSD17B10 Q99714 1/20 0.33
VNN1 O95497 1/20 0.32
TSHR P16473 1/20 0.32
CYP46A1 Q9Y6A2 1/20 0.32
OPRM1 P35372 2/20 0.31
OPRK1 P41145 1/20 0.31
OPRL1 P41146 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23536632 0.83 VNN1 (0.38) CYP2D6CYP2C19CYP3A4MEN1MAPK1
SCHEMBL5974563 0.82 USP2 (0.34) CYP2D6CYP2C19CYP3A4MEN1MAPK1
SCHEMBL12113151 0.78 USP2 (0.46) ALDH1A1USP2TSHROPRK1
SCHEMBL27746269 0.77 CYP46A1 (0.30) CYP46A1
SCHEMBL18040925 0.77 JAK2 (0.35) CYP2D6CYP2C19CYP3A4MEN1MAPK1
SCHEMBL6697462 0.77 L3MBTL1 (0.33) CYP2D6MEN1KMT2AALDH1A1VNN1
SCHEMBL28122499 0.76 CYP2D6 (0.34) CYP2D6CYP2C19CYP3A4MAPK1CYP2C9
SCHEMBL3163627 0.76 ALDH1A1 (0.34) CYP2D6MEN1KMT2AALDH1A1CYP1A2
SCHEMBL21551562 0.76
SCHEMBL1317472 0.75 PTPN11 (0.33) ALDH1A1CYP1A2USP2TSHROPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4339192-A2 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER The Regents of the University of California (US) 2024-03-20 EP disclosed
EP-3478284-B1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER UNIV CALIFORNIA (US) 2023-10-04 EP disclosed
US-20230150942-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-05-18 US disclosed
US-11560356-B2 Compounds and compositions for the treatment of cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-01-24 US disclosed
US-20210009523-A1 Compounds and Compositions for the Treatment of Cancer RASCAL THERAPEUTICS, INC. 2021-01-14 US disclosed
US-8809538-B2 Piperidine-containing compounds and use thereof ARRAY BIOPHARMA INC. (US) 2014-08-19 US disclosed
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-11-10 US disclosed
EP-2375899-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF Array Biopharma, Inc. (US) 2011-10-19 EP disclosed
WO-2010080864-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150942-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TP53, HCCS, CFTR CYP2D6 3128/4885CYP2C19 3797/4885CYP3A4 2168/4885
US-11560356-B2 Compounds and compositions for the treatment of cancer TP53, HCCS, CFTR CYP2D6 3128/4885CYP2C19 3797/4885CYP3A4 2168/4885
US-20210009523-A1 Compounds and Compositions for the Treatment of Cancer TP53, HCCS, CFTR CYP2D6 3128/4885CYP2C19 3797/4885CYP3A4 2168/4885
US-20110275608-A1 PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF NOS1, NOS2, ASS1 CYP2D6 1428/4885CYP2C19 1049/4885CYP3A4 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.